ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0249

Obesity as a possible confusion factor in the scleroderma pattern

Eva Álvarez Andrés1, Marta Novella-Navarro2, Paloma García de la Peña Lefebvre3, Eugenio de Miguel2 and Paz Collado Ramos4, 1Hospital Severo Ochoa de Madrid, Madrid, Spain, 2Hospital Universitario La Paz, Madrid, Spain, 3Facultad ciencias de la Salud HM de la UCJC, Madrid, Spain, 4Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain

Meeting: ACR Convergence 2025

Keywords: Cardiovascular, Imaging, obesity, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The 2023 EULAR criteria for systemic sclerosis reaffirm the diagnostic value of nailfold videocapillaroscopy (NVC), particularly the presence of giant capillaries and capillary loss to detect scleroderma pattern. However, their presence in non-rheumatic patients with cardiovascular risk factors (CVRFs), such as overweight/ obesity (OBE), remains underexplored.The main objective of the study was to evaluate the existence of differences in capillaroscopic findings, in patients with OBE compared to patients with normal weight.

Methods: Longitudinal unicentric observational study carried out in 2020 and 2025, in which the frequency of pathological findings in capillaroscopy is estimated in subjects without rheumatic disease or Raynaud’s phenomenon and compared by presence of OBE (body mass index >26) and normal weight. Exclusion criteria included having Raynaud’s phenomenon or any rheumatological disease, as well as having a CVRF other than OBE.The variables collected were: sociodemographic, weight, height and body mass index, cardiovascular complications, autoimmunity, lipid profile, treatments, tortuosities and NVC alterations (ramified capillaries, enlarged capillaries, giant capillaries, haemorrhages and density loss). The NVC was performed again after 5 years, in 2025, to verify evolution.For the statistics, measures of central tendency and dispersion were used for quantitative variables, and frequencies and percentages for qualitative variables. The outcome variable was OBE yes/no, and the X² test and Fisher’s test were used to compare variables.

Results: 78 subjects were included (78,2% men, mean age 48±13 years), 39 with only obesity as a CVRF and 39 healthy controls without CVRF. The predominant vascular or thrombotic complication was abortion in 15.4% of the subjects, followed by stroke in 2,6% of participants. The presence of tortuosities was observed in 82.1% of the participants, subsequently 44.9% ramified capillaries, 35.9% enlarged capillaries, 33.3% haemorrhages, 28.2% density loss and 26.6% giant capillaries.A statistically significant association was found between OBE and the presence of all the NVC findings, especially giant capillaries and density loss (p < 0,001). These OBE patients were classified as having a scleroderma pattern and remained asymptomatic throughout. Five years later, the analytical and capillaroscopic studies were repeated, revealing the same NVC changes, with no development of rheumatologic pathology in any of them.

Conclusion: Scleroderma-pattern capillaroscopic findings may occur in non-rheumatic patients with OBE. These results underscore the importance of clinical context in interpreting NVC findings and suggest a potential overlap between metabolic and autoimmune microvascular damage.


Disclosures: E. Álvarez Andrés: None; M. Novella-Navarro: None; P. García de la Peña Lefebvre: None; E. de Miguel: AbbVie, 1, 5, 6, BMS, 6, Eli Lilly, 1, 6, Grunenthal, 6, Janssen, 1, 6, MSD, 6, Novartis, 1, 5, 6, Pfizer, 1, 5, 6, Roche, 5, 6, Sanofi, 6, UCB, 6; P. Collado Ramos: None.

To cite this abstract in AMA style:

Álvarez Andrés E, Novella-Navarro M, García de la Peña Lefebvre P, de Miguel E, Collado Ramos P. Obesity as a possible confusion factor in the scleroderma pattern [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/obesity-as-a-possible-confusion-factor-in-the-scleroderma-pattern/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/obesity-as-a-possible-confusion-factor-in-the-scleroderma-pattern/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology